FindTrial
Sign In

Placebo-matching Ubrogepant

DRUG4 trials

Sponsors

Allergan, AbbVie

Conditions

MigraineMigraine, With or Without Aura

Phase 3

Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine
CompletedNCT02828020
AllerganMigraine, With or Without Aura
Start: 2016-07-22End: 2017-12-14Updated: 2019-01-03
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
CompletedNCT02867709
AllerganMigraine, With or Without Aura
Start: 2016-08-26End: 2018-02-26Updated: 2019-03-19
An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine
CompletedNCT02873221
AllerganMigraine, With or Without Aura
Start: 2016-09-13End: 2018-08-02Updated: 2019-08-28
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
RecruitingNCT05125302
AbbVieMigraine
Start: 2022-01-13End: 2027-05-01Target: 1059Updated: 2026-09-14

Related Papers

Efficacy of ubrogepant and atogepant in males and females with migraine: A secondary analysis of randomized clinical trials.
2025-02-011 citations
Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm
Clinical Journal of Pain2022-09-2010 citations
Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain.
2022-08-1713 citations
Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials.
2022-04-259 citations
Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials
Advances in Therapy2021-12-0715 citations
Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II
Cephalalgia2021-04-1936 citations
Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials
Neurology and Therapy2021-02-2025 citations
Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications
Cephalalgia2020-11-2623 citations
An Optional Second Dose of Ubrogepant is Effective in Achieving 2-Hour Pain Freedom in the Acute Treatment of Migraine (166)
Neurology2020-04-1411 citations
Ubrogepant for the Treatment of Migraine
New England Journal of Medicine2019-12-04334 citations
Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine
JAMA2019-11-19268 citations
P.010 Efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine: a single-attack phase 3 study, ACHIEVE II
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques2019-06-013 citations
A.07 Efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine: a single-attack phase 3 study, ACHIEVE I
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques2019-06-011 citations
Efficacy, Safety, and Tolerability of Ubrogepant for the Acute Treatment of Migraine: Results From a Single-Attack Phase 3 Study, ACHIEVE II (S38.008)
Neurology2019-04-0915 citations
Ubrogepant is Effective for the Acute Treatment of Migraine in Patients with an Insufficient Response to Triptans (P3.10-024)
Neurology2019-04-093 citations